SaleMetabolic & GLP-1
Retatrutide
Next-generation GLP receptor agonist studied for metabolic signaling and nutrient partitioning pathways
RETA-CA-26E-0199.637%
11.76 mg / 10 mg
$60.00$70.00CAD
Chemical Structure
Amino Acid Sequence
- CAS
- 221231-10-3
- Formula
- C78H123N23O23S2
- Mol. weight
- 1815.1 g/mol
- Form
- Lyophilized powder
In StockMetabolic & GLP-1
BatchAOD-CA-26F-05
AOD-9604 5mg Canada — 5 mg Lyophilized Vials, Janoshik-Tested
Growth Hormone Fragment
Also known as hGH fragment 176–191
AOD-9604 is a synthetic peptide corresponding to the C-terminal fragment (176–191) of human growth hormone, studied in research for lipolytic-pathway activity.
$80.00CAD
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off.
After that, 10% at 5 vials, 20% at 10 vials.
Purity VerifiedLab TestedSecure
Research Use Only
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
AOD-9604 is a synthetic peptide corresponding to the C-terminal fragment (176–191) of human growth hormone, studied in research for lipolytic-pathway activity.
Experimental models examine its influence on fat metabolism without the growth-promoting signaling of full-length GH.
Purity
Third-party tested for purity, ID, quantity.
Coming Soon
The certificate of analysis for the 5mg lot is being finalised and will be published here as soon as the lab returns it.
Amino Acid Sequence
Chemical Structure
Compound Properties
CAS Number221231-10-3
Molecular FormulaC78H123N23O23S2
Molecular Weight1815.1 g/mol
PubChem CID71300630
Overview
AOD-9604 reproduces the lipolytic domain of human growth hormone while lacking the regions associated with insulin-like growth effects. Research has examined its action on lipid metabolism, including stimulation of lipolysis and inhibition of lipogenesis in cellular and animal models.
Studies have also evaluated its profile in cartilage and joint research models under structured conditions.
History
AOD-9604 was developed from research mapping the lipolytic activity of growth hormone to its C-terminal fragment. The synthetic peptide was characterized to retain fat-metabolism activity independent of GH receptor growth signaling.
Subsequent studies investigated metabolic and musculoskeletal research applications.
Key Research Areas
Research into AOD-9604 focuses on lipid-metabolism and GH-fragment models. Frameworks evaluate lipolytic and antilipogenic signaling and musculoskeletal endpoints under controlled in vitro and preclinical conditions.
3 of the 4 areas below are addressed directly by a paper cited on this page.
Lipid-metabolism and lipolysis models
Addressed on this page by Heffernan 2001, Cox 2015. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Heffernan, M. et al. (2001) — The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice
- Cox, HD. et al. (2015) — Detection and in vitro metabolism of AOD9604
GH-fragment pharmacology
Addressed on this page by Heffernan 2001. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Heffernan, M. et al. (2001) — The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice
Cartilage and joint research frameworks
No paper cited on this page reports on cartilage or joint. This heading marks where AOD-9604 5mg is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Metabolic endpoint studies
Addressed on this page by Ng 2000. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Ng, FM. et al. (2000) — Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone
The references section of this page cites 3 primary papers published between 2000 and 2015 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for AOD-9604 5mg, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Also called
AOD-9604 5mg is also referred to as AOD, and technically as hGH fragment 176–191.
Preclinical only
AOD-9604 5mg is commonly described online in connection with weight loss, appetite suppression and fat reduction. In the research literature the same compound is filed under lipid-metabolism and lipolysis models, GH-fragment pharmacology and cartilage and joint research frameworks.
The 3 papers cited on this page, published between 2000 and 2015 (1 in animal models) describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Every lot of AOD-9604 5mg is independently assayed before it is released, and the certificate for the lot shipped is published rather than summarised. Where a certificate for a current lot is not yet posted, the lot has not yet been released against it.
Researchers who buy AOD-9604 5mg in Canada through Eppix Labs receive a batch-labelled vial whose certificate is published against that lot code, so the material can be matched to its analysis rather than to a generic specification.
- Lyophilized storage
- −20 °C long-term; stable at room temperature in transit
- After reconstitution
- 2–8 °C
- Light
- Protect from UV and direct light
- Freeze-thaw
- Avoid repeated cycles
- Vehicle
- Bacteriostatic water in most published protocols
- Format
- Lyophilized powder
AOD-9604 5mg is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 16 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
Included
- 1 × sealed glass vial in the strength selected (5mg / Single Vial, 5mg / 5-Pack, 5mg / 10-Pack available), batch-labelled
- Batch documentation for the lot shipped, once its certificate is published
- Discreet outer packaging with no product names on the exterior
- Canada Post Xpresspost, tracked, typically 1–2 business days from Canadian stock
Not included
- Bacteriostatic water or any other reconstitution vehicle
- Syringes, needles or filters
- Dosing, administration or protocol guidance of any kind
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of aod 9604. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Related
Researchers also order
Sale
SaleMetabolic & GLP-1
Tirzepatide
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$35.00$40.00CAD
Metabolic & GLP-1
Semaglutide
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$70.00CAD
Metabolic & GLP-1
Eloralintide (LY3841136)
This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
10 mgELOR-CA-26G-1099.810%
12.42 mg / 10 mg
$150.00CAD